BioSpace News Archive

Polpharma Biologics Group announces that its joint venture company with Santo Holding, Bioeq, has received notification by the U.S. Food and Drug Administration that the biologics license application for its proposed biosimilar to Lucentis®, a blockbuster ophthalmological drug containing ranibizumab as active drug substance, has been accepted for review.

Annexon, Inc., a clinical-stage company developing a new class of medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, announced the appointment of Ted Yednock, Ph.D., as chief innovation officer, and the appointment of Larry Mattheakis, Ph.D., as chief scientific officer.

Avivagen Inc. is pleased to announce it will be holding a webcast on Wednesday, October 6th at 10:30 A.M. EDT to discuss its recent sales agreement with AB Vista that was announced on Friday, October 1, 2021.

Covis Pharma GmbH and Norgine B.V. announced data demonstrating the investigational anticoagulant reversal agent, ciraparantag, reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly patients, were published in the European Heart Journal, official journal of the European Society of Cardiology.

Cue Biopharma, Inc. (NASDAQ: CUE), announced today three poster presentations at the Society for Immunotherapy of Cancer’s 36th Anniversary Annual Meeting (SITC 2021), to be held both in Washington, D.C. at the Walter E. Washington Convention Center and virtually November 10-14, 2021.

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, announced today that the California Medicaid Program, Medi-Cal, has placed Twirla on the preferred drug formulary list as of October 1, 2021.

NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced the appointments of Ellen G. Feigal, M.D., and Anne Borgman, M.D., to its Board of Directors.

NKMax, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell therapies, today announced that an abstract highlighting key data from a Phase I SNK01 study in Non-Small Cell Lung Cancer (NSCLC) has been accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10 – 14, 2021, in Washington, D.C.

Candel Therapeutics, Inc. (Nasdaq: CADL), today announced that the Company will present novel biomarker data from the ongoing phase 1 clinical trial of CAN-3110 in recurrent high-grade glioma at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting taking place November 10-14, 2021 in Washington D.C., and virtually.

Enlivex Therapeutics Ltd., a clinical-stage macrophage reprogramming immunotherapy company, announced the peer-reviewed publication of clinical data from the Company’s Phase Ib sepsis trial in Frontiers in Immunology, a leading journal in its field publishing rigorously peer-reviewed research articles.